In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- A Novel In Vitro Glycosylation Approach For Difficult PTMs
- Field Notes: Reducing Risk At Kivi Bio's Interchangeability Conference
- Using Carbon Nanotubes To Pinpoint Optimal Harvest Time in Bioprocessing
- A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
- The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
GUEST COLUMNISTS
-
What To Know About — And How To Apply For — FDA's PreCheck Pilot
FDA has now provided specific eligibility and selection criteria for the PreCheck Pilot Program and a timeline for next steps.
-
MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
Many manufacturing execution system (MES) deployments still operate like it is 2005: a big install, disruptive upgrades, etc. Here's a clearer path forward.
-
A Novel In Vitro Glycosylation Approach For Difficult PTMs
Post-translational modifications of membrane proteins have been historically challenging. Research shows how an in vitro approach brings stability and predictability.
-
Field Notes: Reducing Risk At Kivi Bio's Interchangeability Conference
Risk and fitness for use of interchangeable single-use parts were key themes at the conference. The event exposed communication gaps between suppliers and end-users.
-
Using Carbon Nanotubes To Pinpoint Optimal Harvest Time in Bioprocessing
Cell-free expression systems confound the moment of peak expression. These nanosensors signal through crude lysate for process optimization and endpoint monitoring.
-
A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
Fill/finish operations are famously resource-heavy. Nonetheless, Novo set out to achieve ambitious environmental goals with its $4.1 billion project in North Carolina.
-
The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
The Trump administration has effectively merged national security, trade policy, and drug quality. Now, foreign manufacturers lacking deals face paying a "quality tax."
BIOSIMILAR WHITE PAPERS
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
The Advantages Of A Blended Learning Approach In Operator Training5/30/2024
Explore blended learning and its advantages over traditional operator training methods, which often reduce training to a repetitive but necessary checklist of reading and acknowledging procedures.
-
Process Analytical Technology In The ADC Bioconjugation Process4/23/2025
Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
-
How Lipid Nanoparticles Enable Next-Gen Delivery10/20/2025
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
-
A Scalable Single-Use Two-Step pDNA Purification Process3/6/2024
Evaluate the performance of a single-use two-step plasmid purification process, and see how it compares to the existing three-step purification method.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
BIOSIMILAR APP NOTES & CASE STUDIES
- Real-Time And In-Line Raman Spectroscopy For Glycan Quality Analysis
- Sterilizing Grade Filter Performance With Biologic Drugs
- Extractables In Single-Use Systems Used In ADC Manufacturing
- Exosome Isolation By TFF And Size Exclusion Chromatography
- Replicate Bioscience And Cytiva Collaborate To Deliver srRNA-LNP Vaccines
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Sandoz Confirms European Commission Approval For Ranluspec (ranibizumab), Further Strengthening Overall Biosimilars Leadership And Position In Ophthalmology
- Lupin Receives European Commission Approval For Biosimilar Ranibizumab
- Dr. Reddy's Announces USFDA Acceptance To Review Its Biologics License Application (BLA) For Proposed Interchangeable Biosimilar, Abatacept
- Zydus Launches Biosimilar Aflibercept 2 mg ANYRA For Advancing Ophthalmic Care
- Sandoz Receives US FDA Approval To Expand Enzeevu (aflibercept-abzv) Label For Multiple Retinal Indications
- FDA Approves FILKRI7™ (filgrastim-laha), Accord BioPharma's Biosimilar To NEUPOGEN® (filgrastim)
- U.S. FDA Clears IND For Phase 1 Study Of Henlius' Subcutaneous Daratumumab Biosimilar
- STADA And Bio-Thera Receive European Marketing Authorization For Gotenfia, A Biosimilar To Simponi
NEWSLETTER ARCHIVE
- 02.19.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- 02.12.26 -- Building Enterprise Resilience From QRM Signals
- 01.29.26 -- The Latest In Upstream HCP Mitigation
- 01.15.26 -- SUS Insufficient For 40% Of Biopharma
- 01.08.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance